Your browser doesn't support javascript.
loading
Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy.
Pohling, Christoph; Nguyen, Ha; Chang, Edwin; Schubert, Keith E; Nie, Ying; Bashkirov, Vladimir; Yamamoto, Vicky; Zeng, Yuping; Stupp, Roger; Schulte, Reinhard W; Patel, Chirag B.
Afiliação
  • Pohling C; Division of Biomedical Engineering Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
  • Nguyen H; Department of Electrical and Computer Engineering, Baylor University, Waco, TX 76798, USA.
  • Chang E; Molecular Imaging Program at Stanford, Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Schubert KE; Department of Electrical and Computer Engineering, Baylor University, Waco, TX 76798, USA.
  • Nie Y; Department of Neurosurgery, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
  • Bashkirov V; Division of Biomedical Engineering Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
  • Yamamoto V; Norris Comprehensive Cancer Center, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA.
  • Zeng Y; Department of Electrical and Computer Engineering, University of Delaware, Newark, DE 19716, USA.
  • Stupp R; Department of Neurosurgery; Department of Neurology Division of Neuro-Oncology; Department of Medicine Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
  • Schulte RW; Division of Biomedical Engineering Sciences, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA. Electronic address: rschulte@llu.edu.
  • Patel CB; Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Neuroscience Graduate Program, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA; Cancer Biology Graduate Program, The Univ
Bioelectrochemistry ; 149: 108287, 2023 Feb.
Article em En | MEDLINE | ID: mdl-36306728
Exposing cancer cells to alternating electric fields of 100-300 kHz frequency and 1-4 V/cm strength has been shown to significantly reduce cancer growth in cell culture and in human patients. This form of anti-cancer therapy is more commonly referred to as tumor treating fields (TTFields), a novel treatment modality that has been approved by the U.S. Food and Drug Administration for use in patients with glioblastoma and malignant pleural mesothelioma. Pivotal trials in other solid organ cancer trials are underway. In regards to overall survival, TTFields alone is comparable to chemotherapy alone in recurrent glioblastoma. However, when combined with adjuvant chemotherapy, TTFields prolong median survival by 4.9 months in newly-diagnosed glioblastoma. TTFields hold promise as a therapeutic approach to numerous solid organ cancers. This review summarizes the current status of TTFields research at the preclinical level, highlighting recent aspects of a relatively complex working hypothesis. In addition, we point out the gaps between limited preclinical in vivo studies and the available clinical data. To date, no customized system for TTFields delivery in rodent models of glioblastoma has been presented. We aim to motivate the expansion of TTFields preclinical research and facilitate the availability of suitable hardware, to ultimately improve outcomes in patients with cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Terapia por Estimulação Elétrica / Glioblastoma Idioma: En Revista: Bioelectrochemistry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Terapia por Estimulação Elétrica / Glioblastoma Idioma: En Revista: Bioelectrochemistry Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos